To substantiate our hypothesis empirically, we performed western blot analysis, which demonstrated a marked reduction in the expression levels of PRLR in the 22RV1 prostate cancer cell line following treatment with Osthole. The gene discussed is PRLR; the disease is prostate carcinoma.